What records are connected here?
- Evidence lanes
- 1
- Source years
- 1
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved2Evidence: Animal and lab onlyBrain, nerves and sleep
Dihexa is a lab-made compound derived from a fragment of the hormone angiotensin IV: two amino acids, tyrosine and isoleucine, capped with chemical groups at both ends to make it more stable.1,3 It was designed as a possible dementia drug and has been tested in rats and in the laboratory. FDA states that it has not identified any human exposure data and lacks important information on whether it would cause harm in people.2,3 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,6
| What it is | A modified dipeptide: FDA’s substance registry records it as N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide, that is, the two amino acids tyrosine and isoleucine with a chemical group added at each end. Its developers describe it as a stabilized analogue of angiotensin IV.1,3 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists dihexa acetate among substances whose nominations were withdrawn, noting that it has no human exposure data.2 |
| Human evidence | None. FDA states that it has not identified any human exposure data for products containing dihexa acetate.2 |
| Evidence strength | Animal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned |
Dihexa is a synthetic compound that FDA’s substance registry records as N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide, also called PNB-0408 and ATH-1001.1
Its developers made it by chemically modifying a three-amino-acid fragment of an angiotensin IV analogue to make it resistant to breakdown and able to reach the brain.3
A 2014 study reported that dihexa binds to hepatocyte growth factor and boosts signalling through its receptor, c-Met, and that blocking this system in rats removed its effect on learning.4
In rat brain tissue it increased the formation of synapses, the connections between nerve cells, according to the 2013 and 2014 studies.3,4
FDA states that it has not identified any human exposure data on products containing dihexa acetate by any route, and that it lacks important information on whether it would cause harm if given to people.2
The published evidence reviewed here comes from rats: dihexa reversed memory deficits caused by the drug scopolamine and by ageing in a water-maze test.3
Evidence-strength label: Animal and lab studies only. How this label is assigned
None of the sources reviewed here reports an approval of dihexa by FDA.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, lists dihexa acetate among bulk substances that were previously in category 2, for substances that may present significant safety risks, and whose nominations were withdrawn by the nominators.2
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Dihexa is not among them.5,6
Whether it has any effect in people, and whether it is safe: FDA has not identified any human exposure data.2
Whether its effects on nerve-cell growth in animals carry other risks, which the sources reviewed here do not assess.3,4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Dihexa: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Dihexa are a bounded selection, not every registration or paper about Dihexa. For the years before Dihexa was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Dihexa as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Dihexa in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; FDA has no human exposure data for it. Evidence comes from rat and laboratory studies. FDA lists dihexa acetate on its compounding safety-risk page among withdrawn nominations. Dihexa is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; FDA has no human exposure data for it. Evidence comes from rat and laboratory studies. FDA lists dihexa acetate on its compounding safety-risk page among withdrawn nominations. Dihexa is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 29, 2021
AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.↗Source date November 29, 2021PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PubMed lists PMID 34827486 in Brain sciences as Journal Article, with publication-date metadata of 2021-11-11 (day precision). PeptideScanner associated the retained record with the identity slug dihexa. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1 with attributed title, venue, publication-date, and type metadata.
Selected records span November 29, 2021 to November 29, 2021. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 34827486 in Brain sciences as Journal Article, with publication-date metadata of 2021-11-11 (day precision). PeptideScanner associated the retained record with the identity slug dihexa. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
The Journal of Pharmacology and Experimental Therapeutics · Official source · Source checked November 16, 2026
The Journal of Pharmacology and Experimental Therapeutics · Official source · Source checked November 16, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026